Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
Study Details
Study Description
Brief Summary
This research study is evaluating a new type of cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced malignant tumor. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced malignant cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients.
It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: iNeo-Vac-P01 Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF; Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01. |
Biological: iNeo-Vac-P01
Neoantigen peptides
Other: GM-CSF
immune adjuvant
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate [2 years]
- Number of participants experiencing clinical and laboratory adverse events (AEs) [1 year]
Secondary Outcome Measures
- Overall Survival Rate [2 years]
- Progression Free Survival [2 years]
Other Outcome Measures
- Measurement of CD4/CD8 T lymphocyte subsets [2 years]
- The polypeptide antigen - induced IFN-γ T cells responses [2 years]
- Peripheral blood T cell receptor sequencing analysis [2 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Must freely sign informed consent;
-
Aged 18 to 75 years old;
-
The expected survival period is more than 6 months;
-
ECOG score is 0 or 1;
-
Patients with advanced tumors who fail to receive standard therapy, and those who are not suitable or refuse standard adjuvant therapy;
-
Advanced malignant cancer diagnosed by pathology and imageology;
-
At least one measurable lesions;
-
To be able to obtain sufficient tumor tissue samples and blood samples for analysis, or to have genomic/exon/transcriptional data of tumor tissues and normal tissues, and the data meet the analysis requirements;
-
The main organs function is normal, such as the heart, liver and kidney;
-
Haematological index:
neutrophil count≥1.5×109/L
hemoglobin≥10g/dL
platelet count≥100×109/L
- Biochemical index:
Total bilirubin is less than or equal to 1.5 times the upper limit of normal value (ULN)
AST and ALT is less than or equal to 2.5 times the upper limit of normal value
Serum creatinine and urea nitrogen (BUN) is less than or equal to 1.5 times the upper limit of normal value
-
Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial;
-
Good compliance, able to follow research protocols and follow-up procedures.
Exclusion Criteria:
-
Diagnosed as other malignant tumor, but cured basal cell carcinoma, thyroid carcinoma, cervical dysplasia etc is excluded;
-
No neoantigen was found in the sequencing data;
-
There have been bone marrow or stem cell transplants;
-
Systemic cancer treatment or other drugs under study were treated within 4 weeks prior to individualized tumor targeted polypeptides treatment;
-
Received other polypeptide inoculation 4 weeks before treatment; Patients may not be vaccinated with other polypeptides 8 weeks after the last individualized tumor targeted polypeptides trentment;
-
Active bacterial or fungal infections identified clinically (>= level 2 of NCI-CTC edition 3);
-
Patients with HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or treated with immunosuppressive drugs;
-
People infected with herpes virus (scabbed for more than 4 weeks is excluded);
-
People infected with respiratory virus (cured for more than 4 weeks is excluded);
-
Severe coronary or cerebrovascular disease, or other diseases that the investigators considered should to be exclusion;
-
Drug abuse, Clinical, psychological or social factor result in affecting informed consent or research implementation;
-
Have a history of drug or polypeptide allergies, or people who are allergic to other potential immunotherapies.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sir Run Run Shaw Hospital | Hangzhou | Zhejiang | China | 310000 |
Sponsors and Collaborators
- Sir Run Run Shaw Hospital
- Hangzhou Neoantigen Therapeutics Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.
- Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, Buanes T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011 Mar 1;128(5):1120-8. doi: 10.1002/ijc.25449.
- INEO-P-002